HGH EVOGENE (HUMAN GROWTH HORMONE)
HGH Evogene is recombinant human growth hormone (GH) safe, with high purity, good quality and without side effects. Growth hormone is used by athletes to embrace pure muscle mass and muscle growth. Many men and women use it to burn fat (weight loss) and slow down the aging process.
HGH Evogene (Growth Hormone) price, description and usage
HGH Evogene is identical to the growth hormone that human body makes. This means you can feel confident and making safe, without side effects growth hormone therapy. Evogene is recombinant Human Growth Hormone – rDNA origin has 191 amino acid sequence and its structure are identical to the dominant form of human pituitary growth hormone.
Evogene: benefits for bodybuilders and fitness competitors!
Except for the treatment of children and adults with reduced growth hormone production, Evogene is used by bodybuilders and fitness competitors! They may experience the following benefits:
Increases of pure muscle mass.
Increases protein synthesis.
Increases Muscle Strength.
Increases of muscle stamina.
Reduces subcutaneous fat.
Better condition of joints and tendons.
Improved condition of the skin.
Healthier hair and nails.
Best anti age product.
Evogene( rHGH) is a sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection ( 0,3% m-Cresol)
Mechanism of Action
Somatropin (as well as endogenous HGH) binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharma- codynamic effects. Some of these pharmacodynamic effects are primarily mediated by IGF-I produced in the liver and also locally (e.g., skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (e.g., lipolysis) [see Clinical Pharma- cology (1.2)].
-Pharmacodynamics Tissue Growth
Effects of HGH Evogene on the tissues of the body can generally be described as anabolic (building up). Like most other protein hormones, GH acts by interacting with a specific receptor on the surface of cells. In children with GHD, the primary and most intensively studied show that action of somatropin is the stimulation of linear growth.
The measurable increase in bone length after administration of somatropin results from its effect on the cartilaginous growth areas of long bones. Studies in vitro have shown that the incorporation of sulfate into proteoglycans is not due to a direct effect of Evogene, but rather is mediated by the somatomedins or insulin-like growth factors (IGFs). The somatomedins, among them IGF-I, are polypeptide hormones which are synthesized in the liver, kidney, and various other tissues. IGF-I levels are low in the serum of hypopituitary dwarfs and hypophysectomized humans or animals, and increase after treatment with somatropin. It is only possible when using by children!
It has been shown that the total number of skeletal muscle cells is markedly decreased in children with short stature lackin endogenous GH compared with normal children, and that treatment with somatropin results in an increase in both the number and size of muscle cells.
For prolonged high dose therapy, somatotropin influences the size of internal organs, and it also increases red cell mass.
Muscle growth is facilitated in part by increased cellular protein synthesis. This synthesis and growth are reflected by nitrogen retention which can be quantitated by observing the decline in urinary nitrogen excretion and blood urea nitrogen following the initiation of somatropin therapy.
Hypopituitary children sometimes experience fasting hypoglycemia that may be improved by treatment with Evogene. In healthy subjects, large doses of somatropin may impair glucose tolerance.
Although the precise mechanism of the diabetogenic effect of somatotropin is not known, it is attributed to blocking the action of insulin rather than blocking insulin secretion. Insulin levels in serum actually increase as somatropin levels increase. Administration of human growth hormone to normal adults and patients with growth hormone deficiency results in increases in mean serum fasting and postprandial insulin levels, although mean values remain in the normal range. In addition, mean fasting and postprandial glucose and hemoglobin A1c levels remain in the normal range.
Somatropin stimulates intracellular lipolysis, and administration of Evogene HGH leads to an increase in plasma free fatty acids and triglycerides. Untreated GHD is associated with increased body fat stores, including increased abdominal visceral and subcutaneous adipose tissue. Treatment of growth hormone deficient patients with somatropin results in a general reduction of fat stores, and decreased serum levels of low density lipoprotein (LDL) cholesterol.
Evogene HGH administration results in an increase in total body potassium and phosphorus and to a lesser extent sodium. This retention is thought to be the result of cell growth. Serum levels of phosphate increase in children with GHD after somatropin therapy due to metabolic activity associated with bone growth. Serum calcium levels are not altered. Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Negative calcium balance, however, may occasionally occur during somatropin treatment.
-Connective Tissue Metabolism
HGH Evogene stimulates the synthesis of chondroitin sulfate and collagen. In adults, this leads to: better condition of joints and tendons, improved appearance of the skin, healthier hair and nails.
Weeks 1-4 use HGH 2.0 IU’s in one injection
Week 5 use HGH 2.5 IU’s in one injection
Week 6 use HGH 3.0 IU’s split into two equal injections of 1.5 IU’s
Week 7 use HGH 3.5 IU’s split into two equal injections of 1.75 IU’s